Campbell Neurosciences Press Releases

trader32176
Posts: 2673
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International and Campbell Neurosciences Announce Preclinical Studies Showing Low Doses of FDA Cleared Immune Stimulant Interleukin-2 Reduces Inflammation Associated Depression in Animal Model

Suicide Prevention Company Rapidly Expanding Pipeline on Immunotherapy of Psychiatric Conditions


https://www.prnewswire.com/news-release ... 92421.html


ELK CITY, Idaho, May 17, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today preclinical data utilizing low doses of the FDA cleared therapeutic interleukin-2 in treatment of inflammation induced depression in an animal model.

The experiments, which are covered in a patent application, demonstrate that low doses of interleukin-2 reduce depressive behavior, which is dependent on a newly identified cellular mechanism.

Given that interleukin-2 at higher doses is approved by the FDA for treatment of melanoma and renal cell cancer, the Company believes that clinical development of this novel approach to depression may possess less regulatory hurdles than other product candidates.

"At Campbell Neurosciences our focus is to create a world in which suicide is a thing of the past," said Kalina O'Connor, President and CEO of Campbell Neurosciences. "The data disclosed today, and the associated patent application are a significant step for our Company in not only detecting suicidal propensities but also having pipeline products for treatment."

Campbell Neurosciences recently announced validation in a clinical trial of its "Campbell Score™" a blood-based test capable of assessing suicidal ideations in a quantitative manner.

"These recent data are an example of the synergistic partnership between Therapeutic Solutions International and Campbell Neurosciences," said Famela Ramos, Vice President of Business Development of Therapeutic Solutions International. "Interleukin-2 is a cancer immunotherapeutic drug that through collaboration we found a novel use in neurology. By continuing to work outside of the box, we strive to rapidly develop novel approaches to the second largest cause of death in young people: suicide."

"Watching the rapid progress of Kalina O'Connor and her team at Campbell Neurosciences is truly inspiring," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "Instead of repositioning potentially dangerous approaches such as ketamine or psychedelic drugs for treatment of depression, the data disclosed today reveals a truly novel research direction to addressing one of the biggest scourges of COVID-19 society: depression. We are excited to watch the clinical translation of this new brain medicine which we call immunotherapy of psychiatry."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE

Therapeutic Solutions International

Related Links


http://www.therapeuticsolutionsint.com
trader32176
Posts: 2673
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Spin-Off Campbell Neurosciences Recruits Global Dealmaker Kenji Funahashi to Advisory Board

Company to Accelerate Commercialization of Suicide Prediction Blood Test Campbell Score


https://www.prnewswire.com/news-release ... 94716.html


ELK CITY, Idaho, May 19, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), stated today its partially owned subsidiary Campbell Neurosciences, the first company to develop a blood based diagnostic test for suicidal ideations, has announced that the internationally renowned transactional lawyer, Mr. Kenji Funahashi, Partner at Wilson Sonsini, has joined its advisory board.

Mr. Funahashi has handled more than $10 billion in financings, mergers and acquisitions, joint ventures, and IPOs, including hundreds of private and public financing transactions for entrepreneurs and investors. He represents technology, life sciences, healthcare, and other growth companies throughout the U.S. and internationally.

"Suicide is the number two cause of death in young people, which despite the increase in new drugs, the rate has been steadily increasing over the past 20 years," said Kenji Funahashi. "I am proud to work with Kalina O'Connor, a visionary who has dedicated her life to defeating suicide and the scientific team she assembled."

Campbell Neurosciences was founded by Kalina O'Connor, and is named after her mother, Kathleen Campbell, who fell a victim to suicide. Kalina's uncle Hugh O'Connor, son of Carroll O'Connor, also was a victim of suicide.

"The depth and breadth of Mr. Funahashi' relations, wisdom, and transactional experiences are difficult to overstate," said Kalina O'Connor, President and CEO of Campbell Neurosciences. "We are honored to join forces with Kenji in tackling this 'silent killer' who has deprived so many of their loved ones."

"We at Therapeutic Solutions International are extremely proud of the accomplishments Ms. O'Connor has been achieving, including completion of two clinical trials significantly ahead of schedule," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "The recruitment of an internationally renowned deal maker like Mr. Funahashi will assist the Company in seeking and forging relationships to bring its diagnostics and therapeutic products to the market in a hyper accelerated timeframe."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

Twitter: @campbellneuros1

SOURCE

Therapeutic Solutions International

Related Links


therapeuticsolutionsint.com
trader32176
Posts: 2673
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Subsidiary Campbell Neurosciences Identifies T Regulatory Cells as a Mechanism of Stem Cell Suppression of Schizophrenia Pathology in an Animal Model

Company Addresses Scientific Studies as it Prepares for FDA Filing to Treat Major Cause of Suicide with Adult Stem Cells


https://www.prnewswire.com/news-release ... 03857.html


ELK CITY, Idaho, June 2, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported today a series of experiments, covered by its >1000 claim patent application filed in September 2020, which demonstrate stem cell activity against schizophrenia is associated with T regulatory cell induction.

The experiments demonstrated that mice, which responded to stem cell therapy possessed increased levels of anti-inflammatory cytokines interleukin-4 and interleukin-10, as well as augmented levels of cells expressing FoxP3, a marker characteristic of T regulatory cells. Depletion of T regulatory cells was capable of reducing some of the symptoms of schizophrenia in mice.

"Schizophrenia is one of the biggest predisposing factors to suicide, we at Campbell Neurosciences vow to work diligently and effectively to make schizophrenia a thing of the past," said Kalina O'Connor, President and CEO of Campbell Neuroscience. "I am thankful to our scientific team and collaborators who are working at breakneck speed to obtain as much data as possible so that we may file an investigational new drug (IND) application with the FDA to initiate clinical trials."

"This data strongly supports immunological involvement in schizophrenia, a condition that despite affecting approximately 1% of the population, is still treated in a very empirical manner with little understanding of the molecular mechanisms of the disease, or the currently used treatments," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "We are hoping to use the immunomodulatory properties of adult stem cells to alter several neurological abnormalities that we and others have identified in schizophrenia. To our knowledge, we are the only group utilizing immunology and stem cells to approach this horrific condition."

"This is exciting data and a prime example of the great synergy between our spin-off, Campbell Neurosciences and Therapeutic Solutions," said Timothy Dixon, President and CEO of Therapeutic Solutions International and co-inventor. "By cross-pollinating our work in immunology and neurology, we are making new discoveries at an incredibly rapid pace and we plan on translating these into patents, IND's, and eventually new medicines to treat patients with terrible condition like schizophrenia and cancer."

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE


Therapeutic Solutions International

Related Links


therapeuticsolutionsint.com
trader32176
Posts: 2673
Joined: Fri Jun 26, 2020 5:22 am

Re: Campbell Neurosciences Press Releases

Post by trader32176 »

Therapeutic Solutions International Spinoff Campbell Neurosciences Reports Reduction of Schizophrenia Activity in Mice Subsequent to Administration of Tolerogenic Dendritic Cells

Company Continues to Advance Technologies Described in its >1000 Claim Patent on Cellular Therapy for Schizophrenia


https://www.prnewswire.com/news-release ... 09916.html


ELK CITY, Idaho, June 10, 2021 /PRNewswire/ -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI), announced today that its subsidiary, Campbell Neurosciences, recently obtained data demonstrating that the administration of tolerogenic dendritic cells in an animal model of schizophrenia resulted in suppression of multiple neurological manifestations of the condition. Of great interest was the association between increased numbers of T regulatory cells and therapeutic activity. Previously the Company reported that administration of T regulatory cells are capable of suppressing schizophrenia.

"It is incredible to contemplate that immunological reactions such as the ability of tolerogenic dendritic cells to induce T regulatory cells can be used to treated neurological diseases. The interplay between the brain and the immune system is the foundation of Campbell Neurosciences, and I am very excited to lead the translation of this very relevant animal study into human clinical trials," stated Dr. James Veltmeyer, Chief Medical Officer of the Company.

Campbell Neurosciences was originally founded as a division of Therapeutic Solutions International and subsequently spun off as an independent company, which is focused on ending suicide using immunology and regenerative psychiatry. The company was founded by Kalina O'Connor, the President and CEO of the Company, whose mother, Kathleen O'Connor, and uncle, Hugh O'Connor (son of Carroll O'Connor), were victims of suicide.

"The only way to put an end to this silent epidemic of suicide is to aggressively approach it as a biological disease and not as a choice that people of weak minds make," said Ms. O'Connor. "I have three young kids; suicide is the second largest cause of death in young people. As a daughter of someone who was a victim of suicide, and as a mother now, I feel like not enough work is being done. That is why I am extremely grateful to our investors, our collaborators, and our team that every day is advancing knowledge to the biological causes of suicide."

Campbell Neuroscience's lead product is the Campbell Score, a clinically validated blood test for prediction of suicidal ideation. Additionally, the Company (TSOI) has 13 patent applications filed covering diagnostics and therapeutic solutions.

"Schizophrenia is a very peculiar disease which possesses numerous immunological connections," said Timothy Dixon, President and CEO of Therapeutic Solutions International. "There is much cross-fertilization that occurs between our two companies, especially from the sense that TSOI is focused on using the immune system to kill cancer, whereas Campbell is using the immune system to detect and to alter neuronal activities. Through these interactions we continually develop new ideas, experiments, patents, and ways of interpreting preclinical and clinical data. It is a real pleasure to collaborate with Campbell Neuroscience on this very important life issue."

About Therapeutic Solutions International, Inc.


Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com, and our public forum is https://board.therapeuticsolutionsint.com/

ir@tsoimail.com

SOURCE


Therapeutic Solutions International

Related Links


https://therapeuticsolutionsint.com/
Post Reply